Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report

Figure 2 Changes in lung lesions before and after medication. A: Changes during the treatment of lung adenocarcinoma (arrow indicates the mass in the left upper lobe); B: Changes during the treatment of lung adenocarcinoma and mediastinal lymph node metastasis (arrow indicates enlarged lymph nodes); C: Inflammation in lung tissues (arrows). D: Pulmonary vasculature changes before and after medication, regular use of anticoagulant drugs and thrombosis disappearance (arrow indicates pulmonary vasculature).